Therefore, we compared the predictive ability of GILncSig with KRAS for survival outcome and found that GILncSig was able to identify pancreatic cancer patients with KRAS mutations who may have a higher mortality rate than the rest of the patients. This evidence concerns the gene KRAS and pancreatic neoplasm.